Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
May 20 , 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company has closed the acquisitions of the assets of Laevoroc Immunology AG (“ Laevoroc Immunology ”) and Laevoroc Chemotherapy AG (“ Laevoroc Chemotherapy ”), pursuant to the asset purchase agreements dated November 28, 2024, and November 30, 2024, respectively, as amended (the “ Agreements ”). Acquisition of LEUMUNA™ and GEMCEDA» Mehr auf thenewswire.com
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announced today that it has signed an agreement with Kerentech Consulting Ltd. ( “Kerentech” ), under which Kerentech will support Helix in its ongoing fundraising efforts. Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financing round of USD 13 million to advance the company's lead therapeutic programs and strategic priorities through 2025 and beyond. The collaboration reflects Helix's commitment to accelerating efforts to secure a stable financial platform and fast-track the development of its pipeline candidates this year, beginning with its lead candidate, Tumor Defense Breaker™ L-DOS47.» Mehr auf thenewswire.com
Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers
Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer ( “COO” ) and Jessica Kourniaktis, DPhil , as Director of Communications of the Company. Ms. Kandziora is a seasoned executive with over 20 years of leadership experience across the biopharma, financial, and consulting sectors, bringing a rare trifecta of administrative acumen, people-centered leadership, and organizational insight to her role as COO of Helix BioPharma. Her long-standing relationship with the Company brings invaluable continuity and deep institutional knowledge to this role, having supported corporate strategy, transformation, and stakeholder engagement for Helix in Europe and North America. She previously served as Corporate Secretary of Helix (2017–2019) and as a strategic consultant to the Company's leadership and Board in the years leading up to her appointment. Alongside these roles, she spent 15 years as an independent Asset Manager, advising clients on corporate development, intellectual property, and strategic investments—primarily in the biopharma space. Ms. Kandziora began her career in the financial industry in 2003, leading complex international projects across Germany, Austria, Italy, and Liechtenstein, and consulting for wealth managers, trustees, and investment funds with a focus on biotechnology, technology, and raw materials. A polyglot with a strong foundation in finance and compliance, Ms. Kandziora holds a Diploma in Management and Hospitality from the WIFI Academy of Applied Sciences in Austria, and is a certified Vocational Trainer in Liechtenstein. She has also completed advanced compliance training with the Institute for Compliance and Quality Management (ICQM) and the Association for Quality Assurance of Financial Services (VQF), reinforcing her ability to navigate complex regulatory and governance environments with confidence and clarity.» Mehr auf thenewswire.com
Unternehmenszahlen
(EUR) | Jan. 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −912,58k | 46,86% |
EBITDA | −909,27k | 50,50% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 27,98 Mio€ |
Anzahl Aktien | 53,02 Mio |
52 Wochen-Hoch/Tief | 0,81€ - 0,12€ |
Dividenden | Nein |
Beta | -0,92 |
KGV (PE Ratio) | −0,97 |
KGWV (PEG Ratio) | 0,03 |
KBV (PB Ratio) | −500,65 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Helix BioPharma Corp. ist als Immun-Onkologie-Unternehmen in Kanada tätig. Es entwickelt L-DOS47 für die Behandlung von nicht-kleinzelligem Lungenkrebs und V-DOS47, das auf den vaskulären epithelialen Wachstumsfaktor-Rezeptor 2 abzielt. Helix BioPharma Corp. hat Kooperationsvereinbarungen mit dem Moffitt Cancer Center geschlossen, um die Pharmakodynamik von L-DOS47 zu untersuchen und die Vorteile einer Kombination von L-DOS47 mit Immun-Checkpoint-Inhibitoren zu ermitteln, und mit ProMab Biotechnologies, Inc. zur Entwicklung einer neuartigen Antikörper- und chimären Antigenrezeptor-T-Zell-Therapie zur Behandlung des Multiplen Myeloms sowie Lizenzvereinbarungen mit Xisle Pharma Ventures Trust und National Research of Council Canada. Der Hauptsitz des Unternehmens befindet sich in Richmond Hill, Kanada.
Name | Helix BioPharma Co. |
CEO | Jacek Antas |
Sitz | Toronto, on Kanada |
Website | |
Börsengang | |
Mitarbeiter | 7 |
Ticker Symbole
Börse | Symbol |
---|---|
Toronto Stock Exchange | HBP.TO |
Pnk | HBPCF |
Frankfurt | HBP.F |
Assets entdecken
Shareholder von Helix BioPharma Co. investieren auch in folgende Assets